Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PSTV
PSTV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PSTV News
Plus Therapeutics (PSTV) Outlines 2026 Goals to Advance REYOBIQ and Expand CNSide Platform
Jan 22 2026
NASDAQ.COM
Plus Therapeutics (PSTV) Provides Business Update with $16.6 Million Cash Position
Jan 22 2026
NASDAQ.COM
Plus Therapeutics (PSTV) to Provide Business Update on January 22, 2026
Jan 21 2026
Newsfilter
TSMC Q4 Net Profit Soars 35%, Igniting AI Demand Surge
Jan 17 2026
Benzinga
Plus Therapeutics Prices Public Offering, Raising $15 Million
Jan 15 2026
NASDAQ.COM
U.S. Retail Sales Rise 0.6% MoM, Tech Stocks Decline
Jan 14 2026
Benzinga
Plus Therapeutics Announces Public Offering Aiming to Raise $15 Million
Jan 14 2026
Benzinga
Bank of America Reports Q4 Net Income of $7.6 Billion, Exceeding Expectations
Jan 14 2026
Benzinga
Plus Therapeutics (PSTV) Launches 39.47M Unit Offering to Raise $15M, Shares Plunge 35%
Jan 14 2026
seekingalpha
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
Jan 14 2026
Benzinga
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
Jan 12 2026
Benzinga
Boot Barn Reports 16% Growth in Q3 Net Sales to $705.6 Million
Jan 12 2026
Benzinga
Plus Therapeutics Engages FDA to Advance REYOBIQ Trial Strategy for Leptomeningeal Metastases
Jan 09 2026
Newsfilter
Plus Therapeutics Advances REYOBIQ Clinical Plans Following FDA Type B Meeting
Nov 24 2025
Newsfilter
Palo Alto Set to Surge by 30%? Check Out 10 Leading Analyst Predictions for Friday
Nov 21 2025
Benzinga
Ascendiant Capital Reaffirms Buy Rating on Plus Therapeutics, Adjusts Price Target to $19
Nov 21 2025
Benzinga
Show More News
